Smithfield Trust Co Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Smithfield Trust Co reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 0.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 72,980 shares of the biopharmaceutical company’s stock after selling 620 shares during the period. Smithfield Trust Co’s holdings in Pfizer were worth $1,933,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $26,000. Gladius Capital Management LP increased its position in Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares during the period. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the 4th quarter worth $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer in the 4th quarter worth about $31,000. Finally, Teachers Insurance & Annuity Association of America purchased a new position in shares of Pfizer during the third quarter valued at about $35,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Down 2.0 %

Shares of Pfizer stock opened at $25.72 on Wednesday. The company has a 50-day simple moving average of $26.32 and a two-hundred day simple moving average of $27.28. The stock has a market capitalization of $145.73 billion, a PE ratio of 18.24, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the previous year, the business earned $0.10 EPS. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.69%. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.06% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have commented on PFE. Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Bank of America restated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Guggenheim reaffirmed a “buy” rating and issued a $33.00 price target on shares of Pfizer in a research note on Monday, February 10th. Wolfe Research started coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Finally, Citigroup reduced their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and an average price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.